Are the high-costs of MS disease-modifying therapies justified?

Gavin Giovannoni; Chris Hawkes; Michael Levy; Emmanuelle Waubant

doi:10.1016/j.msard.2018.02.018

Are the high-costs of MS disease-modifying therapies justified?

Gavin Giovannoni, Chris Hawkes, Michael Levy, Emmanuelle Waubant

School of Medicine

Research output: Contribution to journal › Editorial › peer-review

Original language	English (US)
Pages (from-to)	A3-A5
Journal	Multiple Sclerosis and Related Disorders
Volume	20
DOIs	https://doi.org/10.1016/j.msard.2018.02.018
State	Published - Feb 1 2018

ASJC Scopus subject areas

Neurology
Clinical Neurology

Access to Document

10.1016/j.msard.2018.02.018

Cite this

@article{30a850c4536f4d468b52461dca673349,

title = "Are the high-costs of MS disease-modifying therapies justified?",

author = "Gavin Giovannoni and Chris Hawkes and Michael Levy and Emmanuelle Waubant",

year = "2018",

month = feb,

day = "1",

doi = "10.1016/j.msard.2018.02.018",

language = "English (US)",

volume = "20",

pages = "A3--A5",

journal = "Multiple Sclerosis and Related Disorders",